Normal baseline cardiac ejection fraction >= 50%Xx_NEWLINE_xXIf cardiac function assessment is clinically indicated or performed: participants will be ineligible if left ventricular ejection fraction (LVEF) is less than normal per institutional guidelines, or < 55%, if the threshold for normal is not otherwise specified by institutional guidelinesXx_NEWLINE_xXEjection fraction of >= 50% by gated radionuclide studyXx_NEWLINE_xXPatients who have had an echocardiogram performed within 6 months prior to step 2 randomization must have ventricular ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% or >= within normal limits for the institutionXx_NEWLINE_xXSTEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must have left ventricular ejection fraction (LVEF) >= 50% or >= lower limit of normal for the institution by echocardiogram within 14 days prior to step 3 crossover registrationXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by radionuclide angiogramXx_NEWLINE_xXEjection fraction of >= 50%Xx_NEWLINE_xXEjection fraction of >= 50% by radionuclide angiogramXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogramXx_NEWLINE_xXEjection fraction of >= 50% by radionuclide angiogramXx_NEWLINE_xXEjection fraction of >= 50% by radionuclide angiogram or echocardiogramXx_NEWLINE_xXPatients must have ejection fraction >= 45% based on echocardiogram performed within 28 days prior to registrationXx_NEWLINE_xXEjection fraction of >= 50% by radionuclide angiogram (for patients on doxorubicin-containing regimens (Groups C, D, E, and F)Xx_NEWLINE_xXLeft ventricular (LV) ejection fraction <50%, evaluation based on the institutional lower limit of normal.Xx_NEWLINE_xXPatients with angina, a cardiac ejection fraction < 50%, or ischemic heart disease are not eligibleXx_NEWLINE_xXParticipants with known congestive heart failure (CHF); if known, patients with left ventricular ejection fraction (LVEF) =< 40% are excludedXx_NEWLINE_xXAll included patients must have normal cardiac function as defined by an ejection fraction of >= 50% and no decrease in wall motion by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction < 50%Xx_NEWLINE_xXCardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if the patient is > 50 years of age, or history of cardiac disease or anthracycline exposure; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologistXx_NEWLINE_xXHistory of myocardial infarction =< 6 months, current symptomatic CHF or left ventricular ejection fraction (LVEF) < 40% or > grade 2 diastolic dysfunction, with no symptoms or signs of heart failureXx_NEWLINE_xXHistory of ejection fraction drop below the lower limit of normal with trastuzumab and/or pertuzumab.Xx_NEWLINE_xXTransthoracic echocardiogram with ejection fraction > 50%Xx_NEWLINE_xXCardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% by echocardiogram =< 28 days prior to registrationXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ?50%. A lower LVEF (?40%) is permissible if a formal cardiologic evaluation reveals no evidence for clinically significant functional impairment, otherwise the subject may not enter the study.Xx_NEWLINE_xXEjection fraction of >= 50% by gated radionuclide study (while not receiving medications for cardiac function)Xx_NEWLINE_xXSubject must have a left ventricular ejection fraction of ? 50%;Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) less than the lower limit of normal (LLN) as assessed by echocardiographyXx_NEWLINE_xXPrior or current cardiomyopathy including but not limited to the following: known hypertrophic cardiomyopathy, known arrhythmogenic right ventricular cardiomyopathy, previous moderate or severe impairment of left ventricular systolic function (left ventricular ejection fraction [LVEF] < 45% on echocardiography or equivalent on multigated acquisition scan [MuGA]) even if full recovery has occurredXx_NEWLINE_xXBaseline left ventricular ejection fraction (LVEF) below the lower limit of normal (LLN) or < 55% measured by echocardiography or institutionâ€™s lower limit of normal (LLN) for MUGAXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 45%Xx_NEWLINE_xXAll included subjects must have normal cardiac function as defined by an ejection fraction of > 50% by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% calculated by echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction greater than or equal to (>=) 50 percentage (%); >=55% (cohort E only)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction >= 35%, or shortening fraction > 25% (for pediatric patients, a normal ejection fraction is required)Xx_NEWLINE_xXLeft ventricular ejection fraction >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction > 50%.Xx_NEWLINE_xXParticipants must have a left ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction of < 45%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) (per institutional normal) determined by echocardiogram or nuclear medicine scan, within 30 days of registrationXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) below the institutional lower limit of normal or <50%, whichever is lower Infections Patients who meet any of the following infection exclusion criteria will be excluded from study entry:Xx_NEWLINE_xXAdequate cardiac function as assessed by cardiac troponin I within normal range; left ventricular ejection fraction ? 50% or institutional lower limit of normal; cumulative anthracycline dose <360 mg/m2 doxorubicin or equivalent.Xx_NEWLINE_xXLeft ventricular ejection fraction > 45% (in children, shortening fraction > 26%)Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40% or shortening fraction >= 25%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45%Xx_NEWLINE_xXParticipants must have a left ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) greater than (>) 50 percent (%) or above the lower limit of the institutional normal range, whichever is lowerXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50%, regardless of whether there are symptoms of heart failureXx_NEWLINE_xXCardiac function: Ejection fraction > 40%Xx_NEWLINE_xXLeft ventricular ejection fraction < 40%Xx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) within 4 weeks of registrationXx_NEWLINE_xXParticipant has left ventricular ejection fraction at rest ? 40%.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) below the institutional lower limit of normal or below 50% Central Nervous System (CNS) Exclusion Criteria:Xx_NEWLINE_xXPatients must have adequate cardiac function as defined as:\r\n* Shortening fraction of ? 27% by echocardiogram, or\r\n* Ejection fraction of ? 50% by radionuclide angiogramXx_NEWLINE_xXEjection fraction < 55% or less than the lower limit of normal of the institutional standard.Xx_NEWLINE_xXParticipants with clinically significant arrhythmias, complex congenital heart disease, or left ventricular ejection fraction (LVEF) <50 percent (%) or shortening fraction (SF) <=28%Xx_NEWLINE_xXSubject has a documented left ventricular ejection fraction > 50%Xx_NEWLINE_xXEjection Fraction >= 45%Xx_NEWLINE_xXAbnormal left ventricular ejection fraction (less than the lower limit of normal for a patient of that age at the treating institution or <45%, whichever is lower).Xx_NEWLINE_xXCardiac: left ventricular ejection fraction at rest must be ? 45%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ?55% (or the institutional lower limit of normal [LLN]) as evidenced on ECHO.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) below the institutional lower limit of normal or below 50 percent (%), whichever is lower General Exclusion CriteriaXx_NEWLINE_xXLeft ventricular ejection fraction >= 45% or fractional shortening >= 28%Xx_NEWLINE_xXEjection fraction >= 45%Xx_NEWLINE_xXCardiac ejection fraction < 45%Xx_NEWLINE_xXCardiac ejection fraction < 35%Xx_NEWLINE_xXAny patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%Xx_NEWLINE_xXSystolic cardiac function will be assessed at screening if clinically indicated by history and physical; only patients with left ventricular ejection fraction (LVEF) >= 50% will be eligible for enrollmentXx_NEWLINE_xXAny patient known to have an left ventricular ejection fraction (LVEF) less than or equal to 45%Xx_NEWLINE_xXLeft ventricular ejection fraction < 40%, symptomatic coronary artery disease, or uncontrolled arrhythmiasXx_NEWLINE_xXPART I: Baseline left ventricular ejection fraction (LVEF) by 2 dimensional (2D) echocardiogram >= 53%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) within normal institutional limitsXx_NEWLINE_xXWithin 4 weeks prior to study enrollment: Ejection fraction of >= 50% by radionuclide angiogramXx_NEWLINE_xXCardiac ejection fraction >= 50% as determined by screening echocardiogramXx_NEWLINE_xXEchocardiogram demonstrated left ventricular ejection fraction >= 40%.Xx_NEWLINE_xXLeft ventricular ejection fraction > 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 45%Xx_NEWLINE_xXAny patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%Xx_NEWLINE_xXLeft ventricular ejection fraction < 40% as measured on transthoracic echocardiogramXx_NEWLINE_xXPatients with impaired cardiac function as evidenced by ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologistXx_NEWLINE_xXLeft ventricular ejection fraction > 45% or shortening fraction > 26%Xx_NEWLINE_xXTREATMENT WITH SJCAR19: Left ventricular ejection fraction > 40%, or shortening fraction >= 25%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) (echocardiogram [echo]) >= lower limit of normal (LLN).Xx_NEWLINE_xXCardiac: Asymptomatic or if symptomatic, then left ventricular ejection fraction (LVEF) at rest must be >= 40% and must improve with exercise.Xx_NEWLINE_xXAdequate cardiac function defined as shortening fraction of ? 27% or ejection fraction ? 45%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40%.Xx_NEWLINE_xXBaseline cardiac ejection fraction must be >= 40 %.Xx_NEWLINE_xXLeft ventricular ejection fraction of at least 45% by either echocardiography or radionucleotide angiographyXx_NEWLINE_xXKnown left ventricular ejection fraction (LVEF) < 40%. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF 40%?50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriateXx_NEWLINE_xXPatients who have a left ventricular ejection fraction (LVEF) < 45% at screening.Xx_NEWLINE_xXLeft ventricular ejection fraction ? 45% or fractional shortening ? 28%, and no clinically significant electrocardiogram (ECG) findingsXx_NEWLINE_xXLeft Ventricular Ejection Fraction (LVEF) >/=50% HER2-Expressing Breast Cancer-Specific Inclusion CriteriaXx_NEWLINE_xXMust have left ventricular ejection fraction > 50%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 50%.Xx_NEWLINE_xXCardiac ejection fraction of >= 45%Xx_NEWLINE_xXSTRATUM B: Participants with abnormal left ventricular ejection fraction (LVEF) on screening, defined as > 10% below lower limit of normalXx_NEWLINE_xXPatients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction (LVEF) < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate, to be eligibleXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%;Xx_NEWLINE_xXDecreased cardiac function as evidenced by a left ventricular ejection fraction of < 45%Xx_NEWLINE_xXAny patient known to have an left ventricular ejection fraction (LVEF) =< 45 percent (%)Xx_NEWLINE_xXBaseline left ventricular ejection fraction value <50% or shortening fraction of <27%Xx_NEWLINE_xXHas a left ventricular ejection fraction (LVEF) ?50% by either an ECHO or MUGA within 28 days before registrationXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiographyXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) below institutional lower limit of normal or <50%, whichever is lowerXx_NEWLINE_xXUncontrolled cardiac disease, or myocardial infarction within the last 12 months, or left ventricular ejection fraction (LVEF) < 50%, or QTcF interval > 470 msecXx_NEWLINE_xXWithin two weeks prior to enrollment: Left ventricular ejection fraction (LVEF) >= 50% as determined an echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 55%Xx_NEWLINE_xXNo uncontrolled or severe cardiac disease. Baseline ejection fraction (by nuclear imaging or echocardiography) must by ? 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= ULN (institutional limit)Xx_NEWLINE_xXCardiac ejection fraction of >= 45%Xx_NEWLINE_xXCardiac: left ventricular ejection fraction < 35%Xx_NEWLINE_xXLeft ventricular ejection fraction > 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiographyXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45%Xx_NEWLINE_xXHave left ventricular ejection fraction (LVEF) ?50% assessed within 28 days prior to enrollment.Xx_NEWLINE_xXSymptomatic cardiac disease including ventricular dysfunction, left ventricular ejection fraction < 40%, symptomatic coronary artery disease or symptomatic arrhythmiasXx_NEWLINE_xXLeft Ventricular Ejection Fraction (LVEF) < 50%, or a history of clinically significant decrease in LVEF during previous treatment with trastuzumab or (ado-)trastuzumab emtansine;Xx_NEWLINE_xXOrgan dysfunction\r\n* Cardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist\r\n* Pulmonary: \r\n** Diffusing capacity of the lungs for carbon monoxide (DLCO) < 40%, total lung capacity (TLC) < 40%, forced expiratory volume in the first second of breath (FEV1) < 40% and/or receiving supplementary continuous oxygen\r\n** The FHCRC PI of the study must approve of enrollment of all patients with pulmonary nodulesXx_NEWLINE_xXParticipants with known congestive heart failure, symptomatic or Left ventricular (LV) ejection fraction <50% or shortening fraction <27% and participants with congenital long QT syndrome, bradyarrhythmias, or QT interval (QTc)>480 milliseconds on at least 2 separate electrocardiograms (ECG).Xx_NEWLINE_xXEjection fraction of >= 55% by gated radionuclide studyXx_NEWLINE_xXLeft ventricular ejection fraction < 50% or institutional lower limit of normal, whichever is lowerXx_NEWLINE_xXAbnormal left ventricular ejection fraction on echocardiography or MUGA (less than the lower limit of normal for a patient of that age at the treating institution or <45%, whichever is lower).Xx_NEWLINE_xXLeft ventricular ejection fraction > 30%Xx_NEWLINE_xXKnown cardiac ejection fraction of > or = 45% within the past 3 monthsXx_NEWLINE_xXEchocardiogram demonstrating left ventricular ejection fraction (LVEF) >= 35%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction < 35%Xx_NEWLINE_xXHistory of congestive heart failure and/or an left ventricular ejection fraction (LVEF) < 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ejection fraction (EF) >= of 50% (by echocardiogram or MUGA scan within 12 weeks of registration), within 2 weeks of registration (except where specified otherwise)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of institutional normal as assessed by echocardiographyXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < institutional lower limit of normal or < 50%Xx_NEWLINE_xXLeft ventricular ejection fraction of > 40%.Xx_NEWLINE_xXLeft Ventricular Ejection Fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO)Xx_NEWLINE_xXEjection fraction > 45%Xx_NEWLINE_xXHistory of congestive heart failure and cardiac ejection fraction =< 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of >= 50%Xx_NEWLINE_xXFULL STUDY INCLUSION CRITERIA: Left ventricular ejection fraction (LVEF) >= 50% or the lower limit of normal (LLN) according to local institution ranges of normalityXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40%, no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities, within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) greater than or equal to (>/=) 40 percent (%)Xx_NEWLINE_xXCardiac: Uncontrolled clinically significant arrhythmias; clinical evidence of significant congestive heart failure (CHF) (NYHA Class III or IV); left ventricular ejection fraction (LVEF) < 50% by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) <50% at screening.Xx_NEWLINE_xXAdequate cardiac function with left ventricular ejection fraction >= 40%. No uncontrolled arrhythmias or symptomatic cardiac diseaseXx_NEWLINE_xXPatients with left ventricular ejection fraction (LVEF) < 40%Xx_NEWLINE_xXCardiac ejection fraction >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiographyXx_NEWLINE_xXAny of the following:\r\n* Correct QT (QTc) prolongation (defined as a QTc interval >= 500 msecs)\r\n* Left ventricular ejection fraction (LVEF) < institutional lower limits of normal (LLN)\r\n* Frequent ventricular ectopy\r\n* Evidence of ongoing myocardial ischemiaXx_NEWLINE_xXLeft ventricular ejection fraction < 35%Xx_NEWLINE_xXCardiac ejection fraction at rest must be >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) (institutional limit)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN)Xx_NEWLINE_xXAbnormal left ventricular ejection fraction on echocardiography (less than the lower limit of normal for a patient of that age at the treating institution or < 45%)Xx_NEWLINE_xXHave a 2-dimensional (2D) echocardiogram with left ventricular ejection fraction = or > 45% in order to receive epirubicin; subjects with inadequate ejection fraction (EF) or other contraindication can proceed on study without the use of epirubicinXx_NEWLINE_xXLeft ventricular ejection fraction >= 35%Xx_NEWLINE_xXEjection fraction less than 40% by echocardiographyXx_NEWLINE_xXCardiac left ventricular ejection fraction >= 50% at restXx_NEWLINE_xXLeft ventricular ejection fraction >= 50%Xx_NEWLINE_xXAdequate cardiopulmonary reserve defined as follows as assessed within 4 months of study entry:\r\n* Predicted postoperative forced expiratory volume FEV1 > 1L\r\n* Normal left ventricular function (ejection fraction EF ? 45%) and right ventricular function\r\n* No pulmonary hypertension noted on preoperative transthoracic echocardiographyXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 50%Xx_NEWLINE_xXParticipants must have normal cardiac ejection fraction (per label, as defined as institutional normal)Xx_NEWLINE_xXLeft ventricular ejection fraction at or above institutional lower limits of normal (by echocardiogram within 12 weeks of registration)Xx_NEWLINE_xXMust have left ventricular ejection fraction >= 50%Xx_NEWLINE_xXMust have left ventricular ejection fraction > 50%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction > 40%, or shortening fraction >= 25%Xx_NEWLINE_xXEjection fraction >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction < 50%Xx_NEWLINE_xXEjection fraction > 50% by echocardiogram or radionuclide studyXx_NEWLINE_xXAdequate cardiac function with left ventricular ejection fraction (LVEF) ? 55% at baseline.Xx_NEWLINE_xXCardiac ejection fraction < 40% or symptomatic coronary artery disease or uncontrolled arrhythmiaXx_NEWLINE_xXShortening fraction >= 28% or ejection fraction (LVEF) >= 55%, as well asXx_NEWLINE_xXLeft ventricular ejection fraction of at least 40% (myeloablative regimen 1, reduced intensity regimen 3)Xx_NEWLINE_xXLeft ventricular ejection fraction of at least 30% (nonmyeloablative regimen 2)Xx_NEWLINE_xXHave adequate cardiac function as assessed by echocardiogram, with an ejection fraction (EF) > 45%Xx_NEWLINE_xXSignificant cardiovascular abnormalities as defined by any one of the following: congestive heart failure, clinically significant hypotension, symptomatic coronary artery disease, or a documented ejection fraction of < 45%; any patient with an ejection fraction (EF) of 45-49% must receive clearance by a cardiologist to be eligible for the trialXx_NEWLINE_xXPatients with left ventricular ejection fraction < 50% or 10% decrease from baseline on echocardiogram after anthracycline based chemotherapyXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) below 45% or lifetime exposure to anthracyclines over 350mg/m2 of daunorubicin equivalentXx_NEWLINE_xXAbsence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction >= 35%Xx_NEWLINE_xXCardiac ejection fraction greater than or equal to 50% by echocardiogramXx_NEWLINE_xXPatients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] greater than or equal to 50%)Xx_NEWLINE_xXPatients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] >/= 45%)Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40%Xx_NEWLINE_xXAdequate cardiac function with a left ventricular ejection fraction >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 50%Xx_NEWLINE_xXShortening fraction >= 27% or ejection fraction >= 50%, no clinical congestive heart failureXx_NEWLINE_xXAdequate cardiac function with left ventricular ejection fraction >= 40%Xx_NEWLINE_xXSystolic heart failure defined as left ventricular ejection fraction =< 45%Xx_NEWLINE_xXSubjects must have a left ventricular ejection fraction (LVEF) of >= 45%Xx_NEWLINE_xXCardiac ejection fraction (EF) < 40%Xx_NEWLINE_xXHistory or presence of heart failure or left ventricular dysfunction with ejection fraction < 40% within the previous 6 months; if >6 months cardiac function within normal limits and free of cardiac-related symptomsXx_NEWLINE_xXLVEF (left ventricular end diastolic function) of >= 45%; LVEF between 45% and 54% must have negative stress test with increase in ejection fraction (EF) of 3-5 points with stressXx_NEWLINE_xXAdequate cardiac function defined as an ejection fraction > 50% or shortening fraction >= 27%.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45%; LVEF assessment must have been performed within 8 weeks of enrollmentXx_NEWLINE_xXBaseline ejection fraction must be >= 40%Xx_NEWLINE_xXCongestive heart failure (NYHA class III or IV) within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollmentXx_NEWLINE_xXAdequate cardiac function with left ventricular ejection fraction >= 40%Xx_NEWLINE_xXShortening fraction of >= 28% or an ejection fraction >= 50%Xx_NEWLINE_xXThe subject has a documented left ventricular ejection fraction > 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) assessed by echocardiogram within 3 months prior to initiation of study treatment indicates an LVEF of >= 50%Xx_NEWLINE_xXBaseline test of ejection fraction must be >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% on ECHO or MUGAXx_NEWLINE_xXAdequate cardiac function as evidenced by left ventricular ejection fraction (LVEF) greater than or equal to 50%) at baseline as determined by echocardiography.Xx_NEWLINE_xXEjection fraction < 30%, or uncontrolled cardiac failureXx_NEWLINE_xXAdequate cardiac function defined as: normal 12 lead electrocardiogram (EKG) with corrected QT interval (QTc) < 450 msec, and either shortening fraction of >= 28% by echocardiogram and qualitatively normal left ventricular function, or ejection fraction of >= 55% by echocardiogramXx_NEWLINE_xXShortening fraction >= 27% or left ventricular ejection fraction >= 50% by echocardiogram within the past 1 year prior to registrationXx_NEWLINE_xXLeft ventricular ejection fraction equal to or greater than normal within 1 month of enrollment; echocardiography (ECHO) scans must be used throughout the studyXx_NEWLINE_xXLeft ventricular ejection fraction ? 45%Xx_NEWLINE_xXLeft ventricular ejection fraction > 45%Xx_NEWLINE_xXAdequate cardiac and pulmonary function; patients with decreased left ventricular ejection fraction (LVEF) =< 40% or diffusion capacity of carbon monoxide (DLCO) =< 50% of predicted will be evaluated by cardiology or pulmonary prior to enrollment on this protocol; patient with left ventricular assist device (LVAD) placement without heart failure symptoms will be allowedXx_NEWLINE_xXEjection fraction > 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 40%Xx_NEWLINE_xXPART 2: Left ventricular ejection fraction > 40% ORXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50% (evaluated by echocardiogram or magnetic resonance imaging [MRI])Xx_NEWLINE_xXPatients who have other medical conditions that would contraindicate treatment with aggressive chemotherapy (including active infection, uncontrolled hypertension, congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled arrhythmia); if the patient's cardiac history is questionable, a measurement of left ventricular ejection fraction should be obtained within 42 days prior to registration; patients with left ventricular ejection fraction < 50% are not eligibleXx_NEWLINE_xXSerious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) below the institution's lower limit of predicted normal.Xx_NEWLINE_xXLeft ventricular ejection fraction < 35%Xx_NEWLINE_xXLeft ventricular ejection fraction at rest must be >= 35%Xx_NEWLINE_xXKnown cardiac ejection fraction < 50%Xx_NEWLINE_xXSymptomatic uncontrolled coronary artery disease or ejection fraction < 40%Xx_NEWLINE_xXKnown cardiac ejection fraction of >= 45% within the past 6 monthsXx_NEWLINE_xXLeft Ventricular Ejection Fraction (LVEF) ? 50%.Xx_NEWLINE_xXLeft ventricular ejection fraction must be evaluated by nuclear medicine scan or echocardiography and measure >= 50%Xx_NEWLINE_xXLeft ventricular >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) ejection fractionXx_NEWLINE_xXBaseline left ventricular ejection fraction (LVEF) >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction at least 45% on appropriate medical therapy; no uncontrolled arrhythmias or symptomatic cardiac diseaseXx_NEWLINE_xXLeft ventricular ejection fraction >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction: < 40% estimated by echocardiogram (ECHO)Xx_NEWLINE_xXPatients with significant lung disease, an ejection fraction less than 40%, or a resting heart rate less than 60/min will not be enrolledXx_NEWLINE_xXLeft ventricular ejection fraction equal or greater than 40%Xx_NEWLINE_xXEjection fraction >= 35%Xx_NEWLINE_xXRECIPIENT: Left ventricular ejection fraction > 40%, preferably by 2-dimensional (2-D) echocardiogram (echo) obtained within 28 days of enrollmentXx_NEWLINE_xXEjection fraction >= 45% on echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction >= 45%; no uncontrolled arrhythmias or uncontrolled symptomatic cardiac diseaseXx_NEWLINE_xXPatients with symptomatic coronary artery disease, uncontrolled congestive heart failure; left ventricular ejection fraction is not required to be measured, however if it is measured, patient is excluded if ejection fraction is < 30%Xx_NEWLINE_xXLeft ventricular ejection fraction > 40%, or shortening fraction >= 25%Xx_NEWLINE_xXLeft ventricular ejection fraction at rest must be >= 35%, or shortening fraction > 25%Xx_NEWLINE_xXCardiac left ventricular ejection fraction (LVEF) > 45%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40%; no uncontrolled arrhythmias or uncontrolled symptomatic cardiac diseaseXx_NEWLINE_xXLeft ventricular end diastolic function (LVEF) of >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction greater than 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (EF) >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction (EF) >= 45% with no uncontrolled arrhythmias or symptomatic heart diseaseXx_NEWLINE_xXAsymptomatic or if symptomatic then left ventricular ejection function (LVEF) at rest must be >= 50% and must improve with exerciseXx_NEWLINE_xXAny patient known to have left ventricular ejection fraction (LVEF) =< 45%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 50% of the lower limit of normal (LLN) according to local institutional rangesXx_NEWLINE_xXCardiac ejection fraction =< 50%Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% by gated radionuclide studyXx_NEWLINE_xXLeft ventricular end diastolic function (LVEF) of >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 35%, or shortening fraction > 25%, unless cleared by a cardiologistXx_NEWLINE_xXLeft ventricular shortening fraction (LVSF) less than 25%Xx_NEWLINE_xXLeft ventricular ejection fraction > 40%, preferably by two dimensional (2-D) echocardiogram (ECHO), obtained within 90 days of enrollment; if the patient has radiological evidence of aortic, renal artery, or coronary artery vasculitis, a left ventricular ejection fraction > 30% is acceptableXx_NEWLINE_xXCardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be >= 50% and must improve with exerciseXx_NEWLINE_xXLeft ventricular ejection fraction at rest must be >= 35%Xx_NEWLINE_xXSymptomatic coronary artery disease or ejection fraction < 40% or other cardiac failure requiring therapy (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if the patient has a history of anthracyclines or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologistXx_NEWLINE_xXLVEF (left ventricular ejection fraction) >= 40%; no uncontrolled arrhythmias or symptomatic cardiac diseaseXx_NEWLINE_xXNormal echocardiogram (ECHO) (Left ventricular ejection fraction [LVEF] has to be within normal, institutional limits)Xx_NEWLINE_xXLeft ventricle ejection fraction (LVEF) >= 30%Xx_NEWLINE_xXEjection fraction below the lower limit of normal (< 50%)Xx_NEWLINE_xXAdequate cardiac function defined as absence of decompensated congestive heart failure or uncontrolled arrhythmia AND left ventricular ejection fraction >= 35% OR fractional shortening > 22%Xx_NEWLINE_xXLeft ventricular ejection fraction > 50%Xx_NEWLINE_xXAdequate cardiac function defined as absence of decompensated congestive heart failure, or uncontrolled arrhythmia and:\r\n* Left ventricular ejection fraction >= 35% or\r\n* Fractional shortening > 22%Xx_NEWLINE_xXShortening fraction > 24% by echocardiogram, or ejection fraction > 30% by radionuclide angiogramXx_NEWLINE_xXEjection fraction >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction < 35%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45%Xx_NEWLINE_xXCardiac: ejection fraction > 45%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 45%Xx_NEWLINE_xXHas cardiac pathology: Participants with known congestive heart failure, symptomatic or left ventricular (LV) ejection fraction <50% or shortening fraction <27% and participants with congenital long QT syndrome, bradyarrhythmias, or QTc >480 msec on at least 2 separate electrocardiograms (ECGs).Xx_NEWLINE_xXClinically significant heart disorders including an ejection fraction of < 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) <40%Xx_NEWLINE_xXCardiac-left ventricular ejection fraction < 40%, symptomatic coronary artery disease, or uncontrolled arrhythmiasXx_NEWLINE_xXHas Left Ventricular Ejection Fraction ? 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% as measured by echocardiogram during screening evaluationXx_NEWLINE_xXCardiac ejection fraction ? 50%. If between 40-49% a cardiology consult is requiredXx_NEWLINE_xXCardiac ejection fraction > 30%Xx_NEWLINE_xXLeft ventricular ejection fraction greater than 45%Xx_NEWLINE_xXVentricular ejection fraction (VEF) =< 55% at baselineXx_NEWLINE_xXStable cardiac condition with a left ventricular ejection fraction of 40% or greater.Xx_NEWLINE_xXLeft ventricular ejection fraction > 45%Xx_NEWLINE_xXAdequate cardiac function defined by a left ventricular ejection fraction (LVEF) ?40%, QTc <450 msec, and no evidence of clinically significant dysrhythmias on ECGXx_NEWLINE_xXCardiac ejection fraction less than 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) equal to or above the lower limit of normal (LLN) at the institution.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 45%Xx_NEWLINE_xXCardiac left ventricular ejection fraction (LVEF) > 45%Xx_NEWLINE_xXKnown history of: cardiac disease, heart failure or decreased left ventricular ejection fraction, significant clinical arrhythmiasXx_NEWLINE_xXLeft ventricular ejection fraction less than 50%Xx_NEWLINE_xXLeft ventricular ejection fraction at rest > 40% within 3 months of registration.Xx_NEWLINE_xXLeft ventricular ejection fraction >= 50% ORXx_NEWLINE_xXAbsence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction ? 40%Xx_NEWLINE_xXPatients must have a left ventricular ejection (LVEF) >= 50% within 56 days of enrollmentXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40%, no uncontrolled arrhythmias or symptomatic cardiac disease.Xx_NEWLINE_xXKnown cardiac ejection fraction of >= 45% within the past 3 monthsXx_NEWLINE_xXMeasurement of left ventricular ejection fraction (LVEF) should be performed in patients with prior anthracycline exposure or known history of arrhythmia or structural heart disease; in these cases, LVEF must be >= 40%Xx_NEWLINE_xXNormal left ventricular ejection fraction, as defined by ejection fraction (EF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower Phase Ib Dose-Escalation Arm B (Venetoclax and Idasanutlin): Received the following within 7 days prior to the initiation of study treatment:Xx_NEWLINE_xXPatients must have a cardiac ejection fraction of >= 40%, or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a 2-D ECHO scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to allogeneic transplantationXx_NEWLINE_xXEjection fraction of >= 50% by radionuclide angiogram or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) </= 40 percent (%) at screeningXx_NEWLINE_xXLeft ventricular ejection fraction >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXEjection fraction of >= 50% by radionuclide angiogram or echocardiogramXx_NEWLINE_xXCardiac insufficiency: left ventricular ejection fraction (LVEF) < 50% or coronary artery disease requiring treatmentXx_NEWLINE_xXCardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction > 40% (within 28 days of treatment start)Xx_NEWLINE_xXCardiac ejection fraction >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction below the lower limit of normalXx_NEWLINE_xXWithin 30 days of registration: Left ventricular ejection fraction (echocardiogram within 6 months permitted) >= 40%Xx_NEWLINE_xXLeft ventricle ejection fraction (LVEF) >= 55%, specimens must be collected within 10 days prior to the start of study treatmentXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogramXx_NEWLINE_xXEjection fraction >= 47% by radionuclide angiogramXx_NEWLINE_xXLeft ventricular ejection fraction at rest >= 40%Xx_NEWLINE_xXAdequate cardiac reserve (ejection fraction [EF] >= 50%)Xx_NEWLINE_xXCardiac ejection fraction has to be >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional normalXx_NEWLINE_xXSubjects who have a left ventricular ejection fraction (LVEF) < 50%, as assessed by echocardiogram performed at screeningXx_NEWLINE_xXBaseline left ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) =< 50%Xx_NEWLINE_xXPatients with known congestive heart failure, symptomatic or left ventricular (LV) ejection fraction < 50% or shortening fraction < 27% are not eligibleXx_NEWLINE_xXEjection fraction < 50% or below the lower limit of the institutional normal range, whichever is lowerXx_NEWLINE_xXLeft ventricular ejection fraction >= 40% or fractional shortening >= 28%Xx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO), within 2 weeks of the first dose of study treatmentXx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)Xx_NEWLINE_xXWith impaired cardiac function as evidenced by ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologistXx_NEWLINE_xXHistory of congestive heart failure and/or an left ventricular ejection fraction (LVEF) < 40%\r\n* Note: patients at increased risk for coronary artery disease or cardiac dysfunction (e.g., > 65 years old [yo], diabetes, history of hypertension, elevated low-density lipoprotein [LDL], first degree relative with coronary artery disease) will undergo full cardiac evaluation and will not be eligible if they demonstrate significant irreversible ischemia on stress thallium or an ejection fraction < 40%Xx_NEWLINE_xXEjection fraction >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% correctedXx_NEWLINE_xXPatients with a left ventricular ejection fraction of < 45%Xx_NEWLINE_xXNormal echocardiogram (ECHO) (left ventricular ejection fraction [LVEF] has to be within normal, institutional limits)Xx_NEWLINE_xXPatients with a left ventricular ejection fraction of < 45%Xx_NEWLINE_xXPatients who have received prior doxorubicin may not have had more than 320 mg/m^2 total dose and must have a normal left ventricular ejection fraction (LVEF) (>= 45%); (this includes Doxil or other liposomally encapsulated doxorubicin preparations)Xx_NEWLINE_xXContraindication to any drug in the chemotherapy regimen, and specifically: LVEF (Left Ventricular Ejection Fraction) < 45% or peripheral neuropathy grade 2Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50%;Xx_NEWLINE_xXSubject has a resting left ventricular ejection fraction (LVEF) of ? 40% obtained by echocardiography.Xx_NEWLINE_xXSevere cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)Xx_NEWLINE_xXleft ventricular ejection fraction (LVEF) of 50% or higher at baselineXx_NEWLINE_xXLeft Ventricular Shortening Fraction (LVSF) ? 28% confirmed by echocardiogram, or Left Ventricular Ejection Fraction (LVEF) ? 45% confirmed by echocardiogram or MUGA within 7 days of screeningXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 55%Xx_NEWLINE_xXSymptomatic congestive heart failure or evidence of left ventricular dysfunction (ejection fraction < 40%) as measured by gated radionucleotide ventriculogram or echocardiogram; active angina pectoris, or uncontrolled hypertensionXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 50%Xx_NEWLINE_xXLeft ventricular ejection fraction > 40% estimatedXx_NEWLINE_xXActive symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if echocardiogram (ECHO) is obtained the left ventricular ejection fraction (LVEF) should exceed 40%Xx_NEWLINE_xXPatients must not have symptomatic congestive heart failure, coronary artery disease, cardiomyopathy, or uncontrolled arrhythmias; either an echocardiogram or MUGA scan with an ejection fraction >= 45% must be obtained within 14 days prior to registration; (the same scan that was used during induction registration must be used for consolidation registration); the ejection fraction must not have dropped >= 10% from the baseline ejection fraction; if patient has had symptoms suggestive of ischemia or congestive heart failure after that cardiac evaluation was done, a repeat study must be obtained prior to registrationXx_NEWLINE_xXLeft ventricular function 40% or greaterXx_NEWLINE_xXAll subjects must have left ventricular ejection fraction ?50%.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) equal to or greater than the institutional lower limit of normal. LVEF must be evaluated within 28 days prior to beginning study therapy.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 40%Xx_NEWLINE_xXLeft ventricular ejection fraction < 45%Xx_NEWLINE_xXLeft ventricular ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologistXx_NEWLINE_xXHave LVEF (left ventricular ejection fraction) <50% at screeningXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% (measured within 28 days of study entry)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 40%Xx_NEWLINE_xXCardiac ejection fraction of >= 40% as measured by resting echocardiogram, with no significant pericardial effusionXx_NEWLINE_xXEjection fraction must be >= 50%Xx_NEWLINE_xXCardiac ejection fraction >= 50%Xx_NEWLINE_xXBaseline left ventricular ejection fraction (LVEF) 50%.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40%Xx_NEWLINE_xXHuman epidermal growth factor receptor 2 (HER-2) status may be pending at initiation of FOLFIRINOX, but must be known prior to starting trastuzumab; if HER-2 is positive, patients must have a left ventricular ejection fraction (LVEF) >= 50%; HER-2 negative patients are not excludedXx_NEWLINE_xXA left ventricular ejection fraction (LVEF) must be > 50Xx_NEWLINE_xXNo Symptomatic Congestive Heart Failure (Ejection Fraction EF ? 50%)Xx_NEWLINE_xXLeft ventricular ejection fraction at rest > 40% within 3 months of registrationXx_NEWLINE_xXParticipant's left ventricular ejection fraction is within normal institutional rangesXx_NEWLINE_xXECHO/MUGA demonstrating left ventricular ejection fraction (LVEF)? the lower limit of institutional normalXx_NEWLINE_xXCardiac: left ventricular ejection fraction (LVEF) at rest ? 35% (RIC cohort) or LVEF at rest ? 40% (FIC cohort), or left ventricular shortening fraction (LVFS) ? 25%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40% or shortening fraction >= 25%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 35% or shortening fraction > 25%Xx_NEWLINE_xXLeft ventricular ejection fraction < 50%.Xx_NEWLINE_xXCardiac ejection fraction >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 50% or the lower limit of normal (LLN) according to local institution ranges of normality.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% for patients enrolling in the HER2 directed therapy armXx_NEWLINE_xXhave major abnormalities documented by echocardiography (ECHO) with Doppler (for example, moderate or severe heart valve function defect and/or left ventricular ejection fraction <50%, evaluation based on the institutional lower limit of normal). For additional details, refer to ECHO protocol.Xx_NEWLINE_xXNormal cardiac ejection fraction of > 45%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ?50% assessed within 28 days prior to randomization.Xx_NEWLINE_xXLeft ventricular ejection fraction (LEF) >= 40%Xx_NEWLINE_xXEjection fraction > 50% on echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 40% within the 21 days prior to randomizationXx_NEWLINE_xXIf cardiac function assessment is clinically indicated or performed: participants will be ineligible if left ventricular ejection fraction (LVEF) is less than normal per institutional guidelines, or < 55%, if the threshold for normal is not otherwise specified by institutional guidelinesXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% performed no more than 4 weeks prior to enrollmentXx_NEWLINE_xXCardiac history of CHF requiring treatment or Ejection Fraction less than or equal to 50% or chronic stable angina;Xx_NEWLINE_xXIf the left ventricular ejection fraction (LVEF) < 40, patients will be excludedXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXVentricular ejection fraction >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) as assessed by baseline echocardiogram at or above the lower limit of normalXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXPHASE II: Left ventricular ejection fraction (LVEF) >= 50% calculated by echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction < 45% in patients with prior anthracycline use or otherwise at risk for left ventricular systolic dysfunctionXx_NEWLINE_xXBaseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiographyXx_NEWLINE_xXResting left ventricular ejection fraction <50% at the time of screeningXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% if patient has known cardiac dysfunction historyXx_NEWLINE_xXShortening fraction >= 28%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 50%, as determined by radionuclide ventriculography (RVG) or echocardiogram within 60 days prior to initiation of protocol therapyXx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)Xx_NEWLINE_xXReduced left ventricular ejection fraction (< 50%) or other evidence of cardiac dysfunction as determined by the investigatorXx_NEWLINE_xXCardiac ejection fraction < 45%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXEjection fraction >= 50% by echocardiogramXx_NEWLINE_xXEjection fraction >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction < 40% or equivalent shortening fraction < 20% in pediatric patientsXx_NEWLINE_xXCardiac ejection fraction >= 45%Xx_NEWLINE_xXSubjects must have a left ventricular ejection fraction (LVEF) of >= 45%Xx_NEWLINE_xXNormal left ventricular ejection fraction (LVEF)Xx_NEWLINE_xXREGISTRATION INCLUSION CRITERIA: Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of > 55% performed no more than 4 weeks prior to randomizationXx_NEWLINE_xXBaseline left ventricular ejection fraction (LVEF) value less than (<) 55 percent (%)Xx_NEWLINE_xXAsymptomatic cardiac function or if symptomatic then left ventricular ejection fraction (LVEF) >= 50% and must improve with exerciseXx_NEWLINE_xXCardiac ejection fraction > 40%Xx_NEWLINE_xXEjection fraction > 40%Xx_NEWLINE_xXCardiac ejection fraction >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction by echocardiogram (ECHO) >= institutional lower limit of normalXx_NEWLINE_xXLeft ventricular ejection fraction (EF) >= 50%Xx_NEWLINE_xXEjection fraction (EF) >= 50% and no uncontrolled angina, symptomatic ventricular arrhythmias, or electrocardiogram (ECG) evidence of active ischemiaXx_NEWLINE_xXAdequate cardiac function as defined as shortening fraction of > 27% OR ejection fraction of > 50%Xx_NEWLINE_xXLeft ventricular ejection fraction > 45% ORXx_NEWLINE_xXUncontrolled arrhythmias or symptomatic heart disease or left ventricular ejection fraction (LVEF) < 45%Xx_NEWLINE_xXResting left ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXPatents who received an anthracycline prior to enrollment must have an ejection fraction ? 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? lower limit of normal (LLN) for the InstitutionXx_NEWLINE_xXPatients must have a left ventricular ejection fraction (LVEF) of >= 60% AND/ORXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >/= 50% within 28 days prior to first dose of study drug administrationXx_NEWLINE_xXEjection fraction >= 35% (within 6 weeks prior to study enrollment)Xx_NEWLINE_xXCardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 40%Xx_NEWLINE_xXCardiac disease with left ventricular ejection fraction of less than 45%Xx_NEWLINE_xXLeft ventricular ejection fraction at least 40%Xx_NEWLINE_xXThe patient has an absence of coexisting medical problems that would significantly increase the risk of the chemotherapy procedure (e.g. poor left ventricular ejection fraction [LVEF<40%])Xx_NEWLINE_xXPrior left chest wall irradiation or a cumulative anthracycline dose of greater or equal to 300 mg/m^2, unless the ejection fraction or fraction shortening is within normal institutional limits, in which case the patient can be enrolledXx_NEWLINE_xXLeft ventricular ejection fraction (EF) >= 45% with no uncontrolled arrythmias or symptomatic heart diseaseXx_NEWLINE_xXCardiac ejection fraction <LLN (lower limit of normal)Xx_NEWLINE_xXLeft ventricular ejection fraction of at least 40%Xx_NEWLINE_xXPatients with a ventricular ejection fraction (=< 30%), or respiratory compromise (FEV1 =< 40%)Xx_NEWLINE_xXCardiac left ventricular function with resting ejection fraction of less than institutional lower limit of normal.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXEjection fraction (EF) < 35% or uncontrolled cardiac failureXx_NEWLINE_xXEjection fraction (EF) >= 35%Xx_NEWLINE_xXLeft ventricular ejection fraction < 35%Xx_NEWLINE_xXHistory of documented congestive heart failure (CHF) or systolic dysfunction (left ventricular ejection fraction [LVEF] < 50%)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) </= institutional lower limit of normal (LLN) by ECHO at the time of transition to this studyXx_NEWLINE_xXCardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologistXx_NEWLINE_xXCardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be >= 50% and must improve with exerciseXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of > 50% by Doppler ultrasound assessmentXx_NEWLINE_xXPatient must have a normal left ventricular ejection fraction (LVEF) (>= 53%); if a patient has a borderline LVEF (40-52%) they may be considered after consultation with cardiology and study principal investigator (PI) and treated per the guidelinesXx_NEWLINE_xXCardiac ejection fraction > 45%Xx_NEWLINE_xXLeft ventricular ejection function < 45%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45%Xx_NEWLINE_xXSubjects > age 60 or with clinical signs of heart disease must have ejection fraction >= 45% left ventricular ejection fraction (LVEF) pre-transplantXx_NEWLINE_xXActive symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if echocardiogram (ECHO) is obtained, the left ventricular ejection fraction (LVEF) should exceed 40%Xx_NEWLINE_xXPediatric patients: normal left ventricular function with ejection fraction > 55% or shortening fraction >= 27%Xx_NEWLINE_xXLeft ventricular ejection fraction < 50% by ECHOXx_NEWLINE_xXNormal cardiac ejection fraction and no evidence of pericardial effusion as determined by an echocardiogramXx_NEWLINE_xXCardiac function - left ventricular ejection fraction >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40%, however, subjects with a LVEF in the range of 40-49% should have cardiology clearance prior to interventionXx_NEWLINE_xXLeft ventricular ejection fraction < 35%Xx_NEWLINE_xXPatients who are receiving trastuzumab must have a left ventricular ejection fraction of >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction of at least 40% (myeloablative regimen 4, reduced intensity regimen 3) or 30% (nonmyeloablative regimen 2)Xx_NEWLINE_xXCardiac ejection fraction < 40%; ejection fraction is required if age > 50 years or there is a history of prior transplant, anthracycline exposure or history of cardiac disease; and poorly controlled hypertension despite multiple antihypertensivesXx_NEWLINE_xXParticipants with a history of chronic heart failure must have cardiac ECHO indicating left ventricular ejection fraction (LVEF) ? 45% within 21 days prior to first dose of study drugXx_NEWLINE_xXAdequate cardiac function defined as shortening fraction of >= 27% or ejection fraction >= 45%Xx_NEWLINE_xXKnown ejection fraction < 50%.Xx_NEWLINE_xXCardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exerciseXx_NEWLINE_xXLeft ventricular ejection fraction < 50%Xx_NEWLINE_xXThe patient has a left ventricular ejection fraction of < 40%Xx_NEWLINE_xXAdequate cardiac function defined as shortening fraction of ? 27% by echocardiogram or ejection fraction ? 45% by gated radionuclide study.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction <50% as determined by echocardiogram (ECHO) performed at screening or within 30 days prior to C1D1Xx_NEWLINE_xXPatients will be ineligible for treatment on this protocol if:\r\n* There is a history of a recent myocardial infarction (within one year)\r\n* There is a history of a past myocardial infarction (more than one year ago) along with current coronary symptoms requiring medications and/or evidence of depressed left ventricular function (left ventricular ejection fraction [LVEF] < 45% by echocardiogram [ECHO])\r\n* There is a current history of angina/coronary symptoms requiring medications and/or evidence of depressed left ventricular function (LVEF < 45% by ECHO)\r\n* There is clinical evidence of congestive heart failure requiring medical management (irrespective of ECHO results)Xx_NEWLINE_xXSubjects who have a history of, or current evidence of uncontrolled cardiovascular disease or a left ventricular ejection fraction (LVEF) <50%Xx_NEWLINE_xXEjection fraction equal or above 40%Xx_NEWLINE_xXCardiac: Left ventricular ejection fraction at rest must be > 40%, or shortening fraction > 26%.Xx_NEWLINE_xXAdequate left ventricular ejection fraction (LVEF) ? 50%Xx_NEWLINE_xXAdequate heart function with echocardiogram demonstrating ejection fraction >= 45% with no evidence of systolic dysfunctionXx_NEWLINE_xXBaseline cardiac echocardiogram scan with left ventricular ejection fraction (LVEF) of >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO)Xx_NEWLINE_xXCardiac ejection fraction within normal limits as measured by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) less than 45%Xx_NEWLINE_xXCardiac left ventricular ejection fraction (LVEF) >= 35%Xx_NEWLINE_xXPatients with poor cardiac function defined as an ejection fraction (EF) < 40% are excludedXx_NEWLINE_xXEjection fraction >= 50% by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction >= 45% or fractional shortening >= 28%Xx_NEWLINE_xXLeft ventricular ejection fraction equal or greater than 40%Xx_NEWLINE_xXPatients must have left-ventricular ejection fraction > 50% at baselineXx_NEWLINE_xXLeft ventricular ejection fraction (EF) < 50%Xx_NEWLINE_xXNo symptoms of uncontrolled cardiac disease, left ventricular ejection fraction >= 40%Xx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Cardiac function: \r\n* Left ventricular ejection fraction >= 50 by gated radionuclide study OR shortening fraction of >= 27% by echocardiogram\r\n* Patient has no ventricular arrhythmias except for benign premature ventricular contractions\r\n* Patient has a corrected QT (QTc) interval =< 450 msXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Left ventricular ejection fraction >= 50 by gated radionuclide study OR shortening fraction of >= 27% by echocardiogramXx_NEWLINE_xXSuboptimal cardiac function as defined by decreased left ventricular ejection fraction < 55% for cohort 1, and < 50% for cohort 2Xx_NEWLINE_xXKnown left ventricular ejection fraction (LVEF) < 50%Xx_NEWLINE_xXLeft Ventricular Ejection Fraction (LVEF) ? 50% Part 1:Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >50% per ECHO or MUGA for patients on the sunitinib arms (Parts 2e and f).Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50%Xx_NEWLINE_xXLeft ventricular EF > 40%.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50 %Xx_NEWLINE_xXEjection fraction of >= 50% by radionuclide angiogramXx_NEWLINE_xXLeft ventricular ejection fraction >= 40% or shortening fraction >= 25%Xx_NEWLINE_xXIf the subject received prior anthracycline therapy, the left ventricular ejection fraction (LVEF) must be within institution's normal limitsXx_NEWLINE_xXEjection fraction < 50%Xx_NEWLINE_xXAdequate cardiac function defined as shortening fraction of >= 27% or ejection fraction >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction of at least 40-45%Xx_NEWLINE_xXCardiac Function a. Patient must have a shortening fraction ? 29% or an ejection fraction ? 40% by ECHO/MUGA.Xx_NEWLINE_xXLVEF (left ventricular ejection fraction) >= 50%Xx_NEWLINE_xXNo history of serious cardiac arrhythmia or ejection fraction (EF) < 50%Xx_NEWLINE_xXLeft ventricular ejection fraction of >= 55% (or institutional lower normal value)Xx_NEWLINE_xXKnown history of: cardiac disease, heart failure or decreased left ventricular ejection fraction, significant clinical arrhythmiasXx_NEWLINE_xXKnown heart failure (ejection fraction [EF] < 40%)Xx_NEWLINE_xXLeft ventricular ejection fraction > 40%, or shortening fraction >= 25%Xx_NEWLINE_xXCardiac function: left ventricular ejection fraction (LVEF) >= 40% or shortening fraction (SF) >= 25%Xx_NEWLINE_xXLeft ventricular ejection fraction < 50% as assessed by echocardiogram or radionuclide angiography.Xx_NEWLINE_xXEjection fraction of >= 50% by radionuclide angiogramXx_NEWLINE_xXPatients with left ventricular ejection fraction (LVEF) < 45% will not be eligibleXx_NEWLINE_xXLeft ventricular ejection fraction (EF) < 50% at baselineXx_NEWLINE_xXSerious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) below the institution's lower limit of predicted normal.Xx_NEWLINE_xXNormal estimated left ventricular ejection fraction and no history of ischemic heart disease requiring revascularization, unless cleared by a cardiologistXx_NEWLINE_xXThe patient has a baseline corrected QT interval (QTc) >480 ms or left ventricular ejection fraction (LVEF) <50% or less than the lower limit of normal.Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ?50% by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction < 50%Xx_NEWLINE_xXEjection fraction (EF) >= 45%Xx_NEWLINE_xXLeft ventricular ejection fractionXx_NEWLINE_xXLeft ventricular ejection fraction < 40 %.Xx_NEWLINE_xXBaseline left ventricular ejection fraction > or = 50%Xx_NEWLINE_xXLeft ventricular ejection fractionXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 40%Xx_NEWLINE_xXImpaired cardiac function defined as left ventricular ejection fraction (LVEF) < 50 % (or below the study site's lower limit of normal) as measured by MUGA or ECHO.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) <40%, as determined by screening echocardiogram (echocardiogram results obtained within 90 days prior to screening are acceptable)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50% by MUGA or echocardiogramXx_NEWLINE_xXNo evidence of clinically significant congestive heart failure, (ejection fraction of 45% or greater)Xx_NEWLINE_xXAdequate cardiac function measured by left ventricular ejection fraction (LVEF) > 50%; if asymptomatic, pre-transplant echocardiogram is adequate; if symptomatic, echocardiogram needs to be repeatedXx_NEWLINE_xXAdequate cardiac function defined as: left ventricular ejection fraction (LVEF) of either >=50% by ECHO or greater than institutional lower limit of normal (LLN) by echocardiogram (ECHO) (while not receiving medications for cardiac function), corrected QT using Bazett's (QTcB) interval <450 milliseconds (msecs).Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional lower limit of normalXx_NEWLINE_xXLeft ventricular ejection fraction greater than 40%, or shortening fraction greater than or equal to 25%Xx_NEWLINE_xXAny patient known to have an left ventricular ejection fraction (LVEF) less than or equal to 45%Xx_NEWLINE_xXAny patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 40%.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of at least 55%Xx_NEWLINE_xXSpirometry with at least 70% of predicted volumes (including FEV1). A left ventricular ejection fraction (LVEF) of 45% or more. All patients will have a screening 2-D Echocardiogram as part of eligibility screening.Xx_NEWLINE_xXMyocardial infarction (MI) within the previous six months, or patients with left ventricular ejection fraction of less than 45% secondary to a more remote MI.Xx_NEWLINE_xXVentricular ejection fraction (VEF) =< 50 % at baselineXx_NEWLINE_xXRecipient must have adequate cardiac function with a left ventricular ejection fraction > 40%.Xx_NEWLINE_xXLeft ventricular ejection fraction >= 35% or shortening fraction > 25%, unless cleared by a cardiologistXx_NEWLINE_xXLeft ventricular ejection fraction > 50% or the institutional LLN within 28 days prior to the first dose of study treatment.Xx_NEWLINE_xXLeft ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 monthsXx_NEWLINE_xXPatients with a left ventricular ejection fraction less than the institutional lower limit of normalXx_NEWLINE_xXEjection fraction >= 50% by radionuclide evaluationXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40%Xx_NEWLINE_xXAdequate cardiac function with left ventricular ejection fraction at least 45% on appropriate medical therapy; no uncontrolled arrhythmias or symptomatic cardiac diseaseXx_NEWLINE_xXEjection fraction < 50% or below the lower limit of the institutional normal range, whichever is lowerXx_NEWLINE_xXCardiac ejection fraction >= 50% without evidence of congestive heart failure (CHF)Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40%Xx_NEWLINE_xXCardiac: left ventricular ejection fraction at rest must be greater than 40% or shortening fraction greater than 20%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40%; no uncontrolled arrhythmias or symptomatic cardiac diseaseXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40%; no uncontrolled arrhythmias or symptomatic cardiac diseaseXx_NEWLINE_xXLeft ventricular ejection fraction of > 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXSignificant cardiac disease (i.e., left ventricular ejection fraction of < 50%, unstable angina, placement of cardiac stents and myocardial infarction within previous 6 months)Xx_NEWLINE_xXPatients with poor cardiac function as defined by an ejection fraction < 40% are excluded (only for patients enrolled on second phase of protocol for leukapheresis)Xx_NEWLINE_xXHas a pre-treatment transthoracic echocardiography (TTE) showing a calculated left ventricular ejection fraction of less than 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50 %Xx_NEWLINE_xXSubject has a left ventricular ejection fraction ?45%.Xx_NEWLINE_xXAbnormal baseline cardiac function defined as an ejection fraction of less than 55%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 35% or shortening fraction > 25%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 35% (within 42 days)Xx_NEWLINE_xXCardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exerciseXx_NEWLINE_xXResting ejection fraction < 50% or fractional shortening < 25%Xx_NEWLINE_xXHistory of congestive heart failure and ejection fraction less than 35%Xx_NEWLINE_xXLeft ventricular ejection fraction at rest must be >= 40%, or shortening fraction > 25%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXKnown history of left ventricular ejection fraction (LVEF) ?45% or less than the institutional lower limit of normal;Xx_NEWLINE_xXAbnormal left ventricular ejection fraction (less than the lower limit of normal for a patient of that age at the treating institution or <45%)Xx_NEWLINE_xXIf in Arm D (doxorubicin and cyclophosphamide), left ventricular ejection fraction (LVEF) >= 50% as measured by echocardiogram (ECHO) within 4 weeks prior to study drug administrationXx_NEWLINE_xXNormal cardiac function (left ventricular ejection fraction >= 50%)Xx_NEWLINE_xXCardiac ejection fraction >= 40%Xx_NEWLINE_xXNormal cardiac function (left ventricular ejection fraction >= 50%)Xx_NEWLINE_xXCardiac ejection fraction > 40%Xx_NEWLINE_xXAdequate cardiac function defined as an ejection fraction of at least 45%Xx_NEWLINE_xXLeft ventricular ejection fraction > 35%Xx_NEWLINE_xXBaseline screening echocardiogram (echo) left ventricular ejection fraction (LVEF) =< 50Xx_NEWLINE_xXEjection fraction of < 50% (by radionuclide angiogram or echocardiogram) or shortening fraction of < 25% (by echocardiogram)\r\n* Note: for instances where both are reported, and one is below the threshold, the site will have the option to re-measure it centrally at the core labXx_NEWLINE_xXIf previously measured, left ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXA normal ejection fraction, as defined by the participantâ€™s institution; only limited echocardiograms (ECHOs) will be used as cardiac evaluation; no other tests are allowed; ECHO is to be done only in HLA-A2 positive participants; If ECHO has been done within 30 days prior to randomization and results showing a normal ejection fraction have been obtained prior to randomization, an additional ECHO is not needed at baselineXx_NEWLINE_xXLeft ventricular ejection fraction > 40%Xx_NEWLINE_xXEjection fraction at rest >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction < 45% and in children-shortening fraction < 26%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45%Xx_NEWLINE_xXEjection fraction of > 47% by radionucleotide angiogram or echocardiogramXx_NEWLINE_xXEjection fraction of > 40% by radionuclide angiogram or echocardiogramXx_NEWLINE_xXAbsence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50%Xx_NEWLINE_xXLeft ventricular ejection fraction ? 40% or fractional shortening ? 28%Xx_NEWLINE_xXCardiac function: ejection fraction > 40%Xx_NEWLINE_xXCardiac function: Ejection fraction at rest ? 45%Xx_NEWLINE_xXPatients must have left ventricular ejection fraction (LVEF) > 45% or within institutional normal limitsXx_NEWLINE_xXPatients with a history of left ventricular (LV) dysfunction will be still candidates for enrollment in the study if they have documented left ventricular ejection fraction (LVEF) recovery (most recent documented LVEF of 50% or higher) for at least 6 months prior to SPECT regardless of current cardiac medication regimenXx_NEWLINE_xXPatients must have normal cardiac ejection fractionXx_NEWLINE_xXParticipants must have normal cardiac ejection fractionXx_NEWLINE_xXSymptomatic cardiac disease including ventricular dysfunction, left ventricular ejection fraction < 45%, symptomatic coronary artery disease or symptomatic arrhythmiasXx_NEWLINE_xXAdequate cardiac function (? NYHA Class II) or normal cardiac function with left ventricular ejection fraction (LVEF) ? 50% at screening.Xx_NEWLINE_xXConfirmed left ventricular ejection fraction ?50% or any cardiac insufficiency > New York Heart Association (NYHA) class II currently or within the past 6 months,Xx_NEWLINE_xXHave major abnormalities documented by echocardiography (ECHO) with Doppler (for example, moderate or severe heart valve function defect and/or left ventricular ejection fraction <50%, evaluation based on the institutional lower limit of normal).Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 40%Xx_NEWLINE_xXSignificant cardiovascular disease including known left ventricular ejection fraction (LVEF) <40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 40% as measured by echocardiography or MUGA scan performed at ScreeningXx_NEWLINE_xXPatient has a cardiac ejection fraction <50%Xx_NEWLINE_xX